Putney continues winning streak with launch of generic chewable Rimadyl

Putney was founded in Portland, ME, in 2006 with the goal of developing a pipeline of 20 generic drugs for the veterinary market, and it's well on the way to moving those products to market. On Thursday, the company announced that it has launched an FDA-approved version of Zoetis' ($ZTS) popular Rimadyl (carprofen) chewable tablets to treat pain in pets. Putney is now the only company that can boast FDA approvals for generics of all three formulations of Rimadyl, which is also available in caplets and as an injectable solution. The chewable generic is Putney's ninth marketed product in animal health and its fourth FDA approval in the last three months. The company estimates that veterinarians will save about 30% on Putney's chewable carprofen over Zoetis' branded version. "Vets can feel free to pass on those savings to pet owners," Putney CEO Jean Hoffman tells FierceAnimalHealth. Release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

Starting next year, drugmakers that market antibiotics for food animals will face tough new FDA rules limiting their use. So now some pharma companies are…

The USDA plans to hold manufacturers of veterinary biotech drugs to new, strict standards on labeling. Although companies will have between four and six years…